Critical evaluation of hormonal therapy for carcinoma of the prostate

被引：80
作者：
Chodak, GW
Keane, T
Klotz, L
Hormone Therapy Study Grp
机构：
[1] Midwest Prostate & Urol Hlth Ctr, Chicago, IL 60640 USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Univ Toronto, Toronto, ON, Canada
来源：
UROLOGY | 2002年 / 60卷 / 02期
关键词：
D O I：
10.1016/S0090-4295(02)01677-1
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：201 / 208
页数：8
相关论文
共 57 条
[1]  
Adib RS, 1997, BRIT J UROL, V79, P235
[2]  
[Anonymous], 1995, Lancet, V346, P265
[3]  
BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO
[4]  
2-9
[5]   Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma [J].
Bazinet, M ;
Zheng, W ;
Begin, LR ;
Aprikian, AG ;
Karakiewicz, PI ;
Elhilali, MM .
UROLOGY, 1997, 49 (05) :721-725
[6]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[7]  
Bolla M., 1999, International Journal of Radiation Oncology Biology Physics, V45, P147, DOI 10.1016/S0360-3016(99)90023-8
[8]  
Byar D P, 1988, NCI Monogr, P165
[9]  
BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO
[10]  
2-C
123456